Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
← catalyst calendarSponsored by Arrowhead Pharmaceuticals (industry) · ARWR — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
105actual
Sites
19
Countries
Denmark, Italy, New Zealand +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-30 | actual | When the study began enrolling |
| Primary completion | 2025-09-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-05 | actual | The whole study's end, after follow-up |
| First posted | 2022-09-13 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-05 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis
Interventions
- Drug: ARO-MMP7 Inhalation Solution
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)
measured Day 1 up to Day 85
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-01-17 · 1.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-11-12 · 738 KB · SAP_001.pdf
Permalink · ARWR's whole pipeline · Catalyst calendar · Every registered study · What changed